-$0.72 EPS Expected for Onconova Therapeutics Inc (ONTX) This Quarter

Equities research analysts expect Onconova Therapeutics Inc (NASDAQ:ONTX) to post ($0.72) earnings per share for the current quarter, according to Zacks. Two analysts have made estimates for Onconova Therapeutics’ earnings. Onconova Therapeutics posted earnings of ($0.54) per share in the same quarter last year, which indicates a negative year-over-year growth rate of 33.3%. The business is scheduled to report its next earnings report on Monday, March 26th.

On average, analysts expect that Onconova Therapeutics will report full-year earnings of ($2.82) per share for the current fiscal year. For the next year, analysts expect that the company will post earnings of ($2.06) per share. Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that cover Onconova Therapeutics.

Onconova Therapeutics (NASDAQ:ONTX) last announced its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.73) by $0.02. The company had revenue of $0.11 million during the quarter, compared to analyst estimates of $0.29 million. Onconova Therapeutics had a negative net margin of 2,855.94% and a negative return on equity of 558.97%.

Several brokerages have weighed in on ONTX. Maxim Group reaffirmed a “buy” rating and set a $6.00 target price on shares of Onconova Therapeutics in a research note on Thursday, November 2nd. HC Wainwright began coverage on shares of Onconova Therapeutics in a research note on Monday, October 9th. They set a “buy” rating and a $6.00 target price for the company. Finally, ValuEngine raised shares of Onconova Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. Onconova Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $7.33.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. boosted its stake in shares of Onconova Therapeutics by 58.4% in the second quarter. Vanguard Group Inc. now owns 87,940 shares of the biopharmaceutical company’s stock valued at $190,000 after purchasing an additional 32,418 shares during the period. Sabby Management LLC boosted its stake in shares of Onconova Therapeutics by 104.0% in the second quarter. Sabby Management LLC now owns 784,000 shares of the biopharmaceutical company’s stock valued at $1,693,000 after purchasing an additional 399,640 shares during the period. Finally, Tyndall Capital Partners L P boosted its stake in shares of Onconova Therapeutics by 91.4% in the second quarter. Tyndall Capital Partners L P now owns 997,022 shares of the biopharmaceutical company’s stock valued at $2,154,000 after purchasing an additional 476,190 shares during the period. 25.44% of the stock is owned by institutional investors and hedge funds.

Onconova Therapeutics (NASDAQ ONTX) opened at $1.51 on Wednesday. Onconova Therapeutics has a 12 month low of $1.46 and a 12 month high of $3.88.

TRADEMARK VIOLATION WARNING: “-$0.72 EPS Expected for Onconova Therapeutics Inc (ONTX) This Quarter” was originally reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this article on another publication, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this article can be viewed at https://www.chaffeybreeze.com/2017/12/06/0-72-eps-expected-for-onconova-therapeutics-inc-ontx-this-quarter.html.

About Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells.

Get a free copy of the Zacks research report on Onconova Therapeutics (ONTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Onconova Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconova Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply